RBC Capital Maintains Outperform on Opus Genetics, Raises Price Target to $11
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $9 to $11.
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $9 to $11.